BiotechTube

Bevacizumab + FOLFIRI + Pelareorep

Phase 2Recruiting
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Ras-mutated Metastatic Colorectal Cancer

Conditions

Ras-mutated Metastatic Colorectal Cancer, mCRC, MSS Metastatic Colorectal Cancer

Trial Timeline

Apr 30, 2026 → Apr 30, 2030

NCT ID
NCT07446322

About Bevacizumab + FOLFIRI + Pelareorep

Bevacizumab + FOLFIRI + Pelareorep is a phase 2 stage product being developed by Oncolytics Biotech for Ras-mutated Metastatic Colorectal Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07446322. Target conditions include Ras-mutated Metastatic Colorectal Cancer, mCRC, MSS Metastatic Colorectal Cancer.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT07446322Phase 2Recruiting

Competing Products

1 competing product in Ras-mutated Metastatic Colorectal Cancer

See all competitors
ProductCompanyStageHype Score
Momelotinib (MMB) + TrametinibGSK plcPhase 1
32

Other Products from Oncolytics Biotech

REOLYSIN + Carboplatin + Paclitaxel + PlaceboPhase 3
69
Pemetrexed and Reolysin (and safety run-in) + Pemetrexed + Docetaxel and Reolysin + DocetaxelPhase 2
44
REOLYSIN + Carboplatin + PaclitaxelPhase 2
44
REOLYSIN® + Carboplatin + PaclitaxelPhase 2
44
REOLYSIN + GemcitabinePhase 2
44